Safety and efficacy of 23-valent polysaccharide pneumococcal vaccine in patients with systemic lupus erythematosus
Objective: to study the safety and efficacy of the 23-valent polysaccharide pneumococcal vaccine (PPV-23) in patients with systemic lupus erythematosus (SLE).Patients and methods. The study included 75 patients with definite diagnosis of SLE at the age of 19–68 years, 10 (13%) of them had high SLE a...
Main Authors: | G. M. Tarasova, B. S. Belov, M. V. Cherkasova, E. A. Aseeva, T. M. Reshetnyak, T. V. Popkova, N. M. Kosheleva |
---|---|
Format: | Article |
Language: | Russian |
Published: |
IMA-PRESS LLC
2021-06-01
|
Series: | Современная ревматология |
Subjects: | |
Online Access: | https://mrj.ima-press.net/mrj/article/view/1148 |
Similar Items
-
Genetically engineered biological agents in therapy for systemic lupus erythematosus
by: Elena Aleksandrovna Aseeva, et al.
Published: (2013-10-01) -
New possibilities of pharmacotherapy for systemic lupus erythematosus: A place of belimumab
by: E. L. Nasonov
Published: (2014-12-01) -
Possibilities and prospects for glucocorticoid withdrawal in systemic lupus erythematosus
by: S. K. Solovyev, et al.
Published: (2020-03-01) -
Treatment of patients with systemic lupus erythematosus without glucocorticoids – myth or reality?
by: S. K. Soloviev, et al.
Published: (2022-02-01) -
Immunogenicity and efficiency of a 23-valent pneumococcal vaccine in patients with rheumatoid arthritis: results of a 5-year follow up study
by: D. V. Bukhanova, et al.
Published: (2018-12-01)